Your contact persons
As part of our commitment to society, our employees and the environment, several ESG rating agencies conduct independent assessments of our ESG profile. Since 2020, the ESG rating agency Sustainalytics has been assessing CHEPLAPHARM's ESG information, since 2022 we have been receiving an ESG rating from S&P, and since 2023 EcoVadis has been conducting a thorough assessment of our sustainability practices every year.
The EcoVadis assessment covers 21 sustainability criteria across four key areas: environment, labour and human rights, ethics, and sustainable procurement.
In our latest assessment, we were awarded a bronze medal and achieved a score of 67 out of 100, placing CHEPLAPHARM among the top 23% (77th percentile) globally.
Sustainalytics uses a rating system on a scale of 0 to 50, with a lower score indicating a better ESG risk rating. In Sustainalytics’ current ESG rating, CHEPLAPHARM has been awarded a score of 21.5 points (‘medium risk’). With this result, CHEPLAPHARM ranks among the top 6% of companies within the ‘Pharmaceuticals’ sector.
In the Corporate Sustainability Assessment by the rating agency S&P, CHEPLAPHARM is currently rated at 27 points. This places us among the top 30% of companies in the pharmaceuticals industry.
More information on ESG topics and how Cheplapharm deals with them can be found in the following documents for download:
